Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mallinckrodt expands rights to imaging agent:

This article was originally published in Clinica

Executive Summary

Mallinckrodt's marketing rights for Molecular Biosystem's imaging agent, FS609, will now encompass Europe, Africa, India and Russia as well as the US. In October, the two companies submitted a PMA to the US FDA for the agent, and they intend to seek market clearance in Europe in early 1997. Mallinckrodt will pay $12.9 million for the rights as well as 40% of product sales to cover royalties and manufacturing. An initial payment of $7.1 million is payable within 30 days, with the remainder becoming due as agreed milestones are met.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT083413

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel